uniQure to Acquire Corlieve Therapeutics for $55M
uniQure to Acquire Corlieve Therapeutics for $55M Upfront Payment
Shots:
- Corlieve to receive $55M upfront in cash and is eligible to receive $52.1M as development milestones for P-I/II and $191M for P-III development and the approvals of AMT-260 in the US and EU. the transaction is anticipated to be completed in Q3’21
- The acquisition will foster Corlieve lead program, AMT-260, and allows to expands uniQure’s pipeline of innovative gene therapies to treat neurological disorders by using miRNA Silencing Technology
- Corlieve has a license agreement with REGENXBIO that includes an exclusive license to AAV9 for the specific genetic target of AMT-260. REGENXBIO received equity in Corlieve and is eligible to receive milestone payments & royalties on net sales of AMT-260
Click here to read full press release/ article | Ref: Globe Newswire | Image: PR Newswire